JP2024109615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024109615A5 JP2024109615A5 JP2024074166A JP2024074166A JP2024109615A5 JP 2024109615 A5 JP2024109615 A5 JP 2024109615A5 JP 2024074166 A JP2024074166 A JP 2024074166A JP 2024074166 A JP2024074166 A JP 2024074166A JP 2024109615 A5 JP2024109615 A5 JP 2024109615A5
- Authority
- JP
- Japan
- Prior art keywords
- strain
- seq
- species
- sequence identity
- belonging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 208000037384 Clostridium Infections Diseases 0.000 claims 5
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 5
- 206010054236 Clostridium difficile infection Diseases 0.000 claims 5
- 241000428313 Anaerotruncus colihominis Species 0.000 claims 4
- 241001464894 Blautia producta Species 0.000 claims 4
- 241000016537 Dorea longicatena Species 0.000 claims 4
- 241001134569 Flavonifractor plautii Species 0.000 claims 4
- 241001246487 [Clostridium] bolteae Species 0.000 claims 4
- 241000193462 [Clostridium] innocuum Species 0.000 claims 4
- 241000193450 [Clostridium] symbiosum Species 0.000 claims 4
- 230000003115 biocidal effect Effects 0.000 claims 3
- 241000874199 Drancourtella massiliensis Species 0.000 claims 2
- 241001601862 Sellimonas intestinalis Species 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 108010078777 Colistin Proteins 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229960004682 cefoperazone Drugs 0.000 claims 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 1
- 229920003174 cellulose-based polymer Polymers 0.000 claims 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
- 229960003346 colistin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960000628 fidaxomicin Drugs 0.000 claims 1
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349914P | 2016-06-14 | 2016-06-14 | |
| US62/349,914 | 2016-06-14 | ||
| JP2019518374A JP7168558B2 (ja) | 2016-06-14 | 2017-06-14 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| PCT/US2017/037498 WO2017218680A1 (en) | 2016-06-14 | 2017-06-14 | Treatment of clostridium difficile infection |
| JP2022172637A JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172637A Division JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024109615A JP2024109615A (ja) | 2024-08-14 |
| JP2024109615A5 true JP2024109615A5 (enExample) | 2025-01-24 |
Family
ID=60664224
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518374A Active JP7168558B2 (ja) | 2016-06-14 | 2017-06-14 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| JP2022172637A Active JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| JP2024074166A Pending JP2024109615A (ja) | 2016-06-14 | 2024-05-01 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518374A Active JP7168558B2 (ja) | 2016-06-14 | 2017-06-14 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| JP2022172637A Active JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12390498B2 (enExample) |
| EP (2) | EP3468573B1 (enExample) |
| JP (3) | JP7168558B2 (enExample) |
| KR (4) | KR20250140643A (enExample) |
| CN (1) | CN109562133A (enExample) |
| AU (2) | AU2017285211B2 (enExample) |
| CA (2) | CA3027917C (enExample) |
| DK (1) | DK3468573T5 (enExample) |
| ES (1) | ES2960053T3 (enExample) |
| FI (1) | FI3468573T3 (enExample) |
| MX (2) | MX2018015522A (enExample) |
| PT (1) | PT3468573T (enExample) |
| WO (1) | WO2017218680A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017218680A1 (en) | 2016-06-14 | 2017-12-21 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| WO2018187272A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| BR112020008552A2 (pt) | 2017-10-30 | 2020-12-29 | Seres Therapeutics, Inc. | métodos e composições para tratamento de resistência a antibiótico |
| AU2018365071B2 (en) * | 2017-11-09 | 2025-09-11 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| EP4410954A3 (en) | 2017-12-11 | 2025-01-15 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| WO2019191694A1 (en) * | 2018-03-29 | 2019-10-03 | Seres Therapeutics, Inc. | Compositions and methods for treating inflammatory bowel diseases |
| BR112020025123A2 (pt) * | 2018-06-19 | 2021-03-23 | 4D Pharma Research Ltd | forma de dosagem compreendendo um produto bioterapêutico vivo |
| CN112888447A (zh) * | 2018-08-17 | 2021-06-01 | 韦丹塔生物科学股份有限公司 | 减少菌群失调和恢复微生物群系的方法 |
| IL265735A (en) | 2019-03-31 | 2019-05-30 | Biomica | A microbial consortium and its uses |
| KR20220063153A (ko) * | 2019-07-17 | 2022-05-17 | 유타대학연구재단 | 클로스트리디아 집합체 조성물 및 비만, 대사 증후군 및 과민성 대장 증후군을 치료하는 방법 |
| GB201911728D0 (en) * | 2019-08-15 | 2019-10-02 | Genome Res Ltd | Bacterial composistions for the treatment of disease |
| EP3858363A1 (en) | 2020-01-28 | 2021-08-04 | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement | Composition for treating intestinal or pulmonary diseases |
| CN115867146B (zh) * | 2020-02-07 | 2025-01-17 | 国际N&H丹麦有限公司 | 用于动物健康的饲料组合物 |
| GB202007452D0 (en) * | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
| WO2022039561A1 (ko) * | 2020-08-21 | 2022-02-24 | 서울대학교산학협력단 | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 |
| KR102296288B1 (ko) * | 2020-12-31 | 2021-09-01 | 주식회사 바이오뱅크힐링 | 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102269966B1 (ko) * | 2021-01-12 | 2021-06-28 | 주식회사 바이오뱅크힐링 | 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN117241809A (zh) | 2021-01-21 | 2023-12-15 | 韦丹塔生物科学股份有限公司 | 用于治疗肝性脑病的组合物和方法 |
| EP4294413A1 (en) * | 2021-02-18 | 2023-12-27 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| WO2022236365A1 (en) * | 2021-05-10 | 2022-11-17 | Microba Ip Pty Ltd | Compositions and methods for treating disease |
| KR102331486B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 비피도박테리움 슈도카테눌라튬 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351146B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 페디오코쿠스 에시디락티시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| US20240335481A1 (en) * | 2021-08-02 | 2024-10-10 | Biobankhealing Inc | Blautia sp. strain, leuconostoc sp. strain, or ruminococcus sp. strain and endoplasmic reticulum derived therefrom, and anti-inflammatory and antibacterial uses thereof |
| WO2023014048A1 (ko) * | 2021-08-02 | 2023-02-09 | 주식회사 바이오뱅크힐링 | 비피도박테리움 속 균주 또는 페디오코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102331484B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 블라우티아 마실리엔시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351145B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102331485B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102331483B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 류코노스톡 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351147B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351148B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 페디오코쿠스 펜토사세우스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102792000B1 (ko) * | 2021-10-21 | 2025-04-08 | 경북대학교 산학협력단 | 신규한 락토바실러스 루테리 psc102 균주 및 이의 용도 |
| KR102337998B1 (ko) * | 2021-11-03 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 로제부리아 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2023075458A1 (ko) * | 2021-10-27 | 2023-05-04 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102337995B1 (ko) * | 2021-11-10 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 아가토바쿨룸 부티리시프로두켄스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102444328B1 (ko) * | 2022-03-11 | 2022-09-19 | 주식회사 바이오뱅크힐링 | 아나에로스티페스 하드루스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102365420B1 (ko) * | 2022-01-04 | 2022-02-23 | 주식회사 바이오뱅크힐링 | 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2023132628A1 (ko) * | 2022-01-04 | 2023-07-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| EP4494484A1 (en) | 2022-03-18 | 2025-01-22 | Meiji Co., Ltd | Collinsella bacteria proliferation controlling composition and use thereof |
| KR102626400B1 (ko) * | 2022-08-31 | 2024-01-19 | 주식회사 바이오뱅크힐링 | 도레아 론기카테나 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2025033635A1 (ko) * | 2023-08-08 | 2025-02-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102620186B1 (ko) * | 2023-08-08 | 2024-01-04 | 주식회사 바이오뱅크힐링 | 리모실락토바실러스 뮤코세 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| KR102620185B1 (ko) * | 2023-08-08 | 2024-01-04 | 주식회사 바이오뱅크힐링 | 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| WO2025033636A1 (ko) * | 2023-08-08 | 2025-02-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102628942B1 (ko) * | 2023-08-08 | 2024-01-26 | 주식회사 바이오뱅크힐링 | 레비락토바실러스 브레비스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| WO2025076184A1 (en) | 2023-10-03 | 2025-04-10 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| WO2025093777A1 (en) | 2023-11-05 | 2025-05-08 | Human Biome Institute S.A. | Functional compositions and methods of use thereof in the treatment and recurrence prophylaxis of clostridioides difficile infection and restoration of healthy microbiota |
| CN117797176B (zh) * | 2024-03-01 | 2024-07-02 | 南京大学 | 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4205A (en) | 1845-09-23 | Spark-arrester | ||
| US132A (en) | 1837-02-25 | Improvement in propelling machinery by magnetism and electro-magnetism | ||
| US3261761A (en) | 1962-05-07 | 1966-07-19 | Arthur W Anderson | Method of freeze drying bacterial cultures |
| CA2232001C (en) | 1995-09-15 | 2002-12-10 | Dale N. Gerding | Methods and compositions for prevention and treatment of clostridium difficile-associated diseases |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| US20090197249A1 (en) | 2004-11-01 | 2009-08-06 | George Mason University | Compositions and methods for diagnosing colon disorders |
| KR101260533B1 (ko) | 2005-03-03 | 2013-05-06 | 가부시키가이샤 메이지 | 면역기능 조정제 |
| US9603876B2 (en) | 2008-09-25 | 2017-03-28 | New York University | Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment |
| GB0916335D0 (en) | 2009-09-17 | 2009-10-28 | Martin W J | Medicaments |
| RS63299B1 (sr) | 2010-02-01 | 2022-07-29 | Rebiotix Inc | Bakterioterapija clostridium difficile kolitisa |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| EP3424515A3 (en) | 2010-08-04 | 2019-06-19 | Thomas Julius Borody | Stool collection devices and methods for using them |
| US9386793B2 (en) | 2010-08-20 | 2016-07-12 | New York University | Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota |
| WO2012098358A1 (en) | 2011-01-20 | 2012-07-26 | Biopharma Technology Ltd | Freeze drying method |
| MX359082B (es) | 2011-05-23 | 2018-09-11 | Washington State Univ Research Foundation | Uso de agentes estabilizantes de pigmento fotosintético para regular la maduración y calidad de frutas y vegetales. |
| ES2662793T3 (es) | 2011-09-14 | 2018-04-09 | Nubiyota Llc | Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos |
| ES2993669T3 (en) * | 2011-12-01 | 2025-01-03 | Univ Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| CN110201003A (zh) | 2012-02-29 | 2019-09-06 | 伊西康内外科公司 | 微生物区系的组合物及与其相关的方法 |
| EP2832859B1 (en) | 2012-03-30 | 2018-07-25 | Ajinomoto Co., Inc. | Diabetes-inducible bacterium |
| WO2013171515A1 (en) | 2012-05-18 | 2013-11-21 | Genome Research Limited | Methods and groups |
| CN102743420A (zh) | 2012-06-06 | 2012-10-24 | 上海交通大学 | 改善肠道菌群结构的方法及应用 |
| WO2014029578A1 (en) | 2012-08-24 | 2014-02-27 | Haldor Topsøe A/S | Method and catalyzed filter element with improved alkali-resistance for flue gas cleaning |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| PL3628161T3 (pl) | 2012-11-23 | 2023-08-07 | Seres Therapeutics, Inc. | Synergistyczne kompozycje bakteryjne i sposoby ich wytwarzania oraz stosowanie |
| HK1219022A1 (zh) * | 2013-02-04 | 2017-03-24 | Seres Therapeutics, Inc. | 填充胃肠道的方法 |
| HK1220495A1 (zh) | 2013-03-14 | 2017-05-05 | Seres Therapeutics, Inc. | 从材料和组合物中检测和富集病原体的方法 |
| RU2015140610A (ru) | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| US9669059B2 (en) | 2013-03-15 | 2017-06-06 | University Of Florida Research Foundation, Incorporated | Butyrogenic bacteria as probiotics to treat clostridium difficile |
| US10076546B2 (en) | 2013-03-15 | 2018-09-18 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| JP2016530239A (ja) | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| CA2926466C (en) | 2013-10-03 | 2021-11-16 | Frederic Bushman | Compositions comprising a defined microbiome and methods of use thereof |
| WO2015077794A1 (en) * | 2013-11-25 | 2015-05-28 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP3082431A4 (en) | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| JP6617935B2 (ja) | 2014-04-10 | 2019-12-11 | 国立研究開発法人理化学研究所 | Ｔｈ１７細胞の誘導のための組成物及び方法 |
| EP3134509A4 (en) | 2014-04-23 | 2017-09-13 | Cornell University | Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract |
| DK3146065T3 (da) | 2014-05-19 | 2025-01-06 | Memorial Sloan Kettering Cancer Center | Methods and compositions for reducing clostridium difficile infection |
| CN113730442A (zh) | 2014-10-31 | 2021-12-03 | 潘德勒姆治疗公司 | 与病症的微生物治疗和诊断有关的方法和组合物 |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| FI3223835T3 (fi) | 2014-11-25 | 2025-06-16 | Memorial Sloan Kettering Cancer Center | Suolen mikrobisto ja gvhd |
| HK1252460A1 (zh) | 2015-05-14 | 2019-05-24 | Crestovo Holdings Llc | 用於糞便菌群移植的組合物以及用於製備和使用它們的方法和用於遞送它們的裝置 |
| KR20180010237A (ko) | 2015-05-21 | 2018-01-30 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 건강 증진을 위한 박테리아 집단 |
| EP3307906B1 (en) | 2015-06-09 | 2020-10-14 | Regents of the University of Minnesota | Methods for detecting risk of having a bloodstream infection |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PL3307288T3 (pl) | 2015-06-15 | 2019-12-31 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| SMT202200174T1 (it) | 2015-06-15 | 2022-05-12 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| SG10201912323VA (en) | 2015-06-15 | 2020-02-27 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EA201890097A1 (ru) | 2015-06-22 | 2018-07-31 | Президент Энд Феллоуз Оф Гарвард Колледж | Индукция регуляторных т-клеток lamina propria |
| RU2018103081A (ru) | 2015-07-08 | 2019-08-08 | Серес Терапеутикс, Инк. | Способы лечения колитов |
| WO2017035188A1 (en) | 2015-08-24 | 2017-03-02 | Nubyiota Llc | Systems and methods for treating a dysbiosis using fecal-derived bacterial populations |
| CN108472315A (zh) | 2015-10-26 | 2018-08-31 | 克雷斯顿沃控股公司 | 用于粪便微生物群相关疗法的组合物及方法 |
| HK1254843B (zh) | 2015-11-20 | 2020-04-17 | 希杰生物科技株式会社 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| BR112018010430A2 (pt) | 2015-11-24 | 2018-11-27 | Seres Therapeutics Inc | composições bacterianas projetadas |
| EP3520801A1 (en) | 2016-03-04 | 2019-08-07 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| US20170290889A1 (en) | 2016-04-11 | 2017-10-12 | New York University | Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| WO2017218680A1 (en) | 2016-06-14 | 2017-12-21 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US11517614B2 (en) | 2016-06-28 | 2022-12-06 | Synthetic Biologics, Inc. | Microbiome protection from oral antibiotics |
| WO2018080477A1 (en) | 2016-10-26 | 2018-05-03 | The Joan & Irwin Jacobs Technion-Cornell Institute | Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols |
| KR20210024481A (ko) | 2018-05-24 | 2021-03-05 | 세레스 테라퓨틱스, 인코포레이티드 | 설계된 박테리아 조성물 및 이의 용도 |
| CN112888447A (zh) | 2018-08-17 | 2021-06-01 | 韦丹塔生物科学股份有限公司 | 减少菌群失调和恢复微生物群系的方法 |
| CN117241809A (zh) | 2021-01-21 | 2023-12-15 | 韦丹塔生物科学股份有限公司 | 用于治疗肝性脑病的组合物和方法 |
-
2017
- 2017-06-14 WO PCT/US2017/037498 patent/WO2017218680A1/en not_active Ceased
- 2017-06-14 CA CA3027917A patent/CA3027917C/en active Active
- 2017-06-14 PT PT178140240T patent/PT3468573T/pt unknown
- 2017-06-14 EP EP17814024.0A patent/EP3468573B1/en active Active
- 2017-06-14 KR KR1020257031130A patent/KR20250140643A/ko active Pending
- 2017-06-14 MX MX2018015522A patent/MX2018015522A/es unknown
- 2017-06-14 CN CN201780049780.0A patent/CN109562133A/zh active Pending
- 2017-06-14 KR KR1020247012234A patent/KR102862927B1/ko active Active
- 2017-06-14 KR KR1020197001044A patent/KR102554351B1/ko active Active
- 2017-06-14 AU AU2017285211A patent/AU2017285211B2/en active Active
- 2017-06-14 KR KR1020237023016A patent/KR102658297B1/ko active Active
- 2017-06-14 FI FIEP17814024.0T patent/FI3468573T3/fi active
- 2017-06-14 CA CA3226196A patent/CA3226196A1/en active Pending
- 2017-06-14 ES ES17814024T patent/ES2960053T3/es active Active
- 2017-06-14 JP JP2019518374A patent/JP7168558B2/ja active Active
- 2017-06-14 DK DK17814024.0T patent/DK3468573T5/da active
- 2017-06-14 EP EP23188649.0A patent/EP4282489A3/en active Pending
-
2018
- 2018-12-13 MX MX2023003461A patent/MX2023003461A/es unknown
-
2022
- 2022-10-27 JP JP2022172637A patent/JP7483828B2/ja active Active
-
2023
- 2023-05-31 US US18/326,511 patent/US12390498B2/en active Active
-
2024
- 2024-05-01 JP JP2024074166A patent/JP2024109615A/ja active Pending
- 2024-08-29 AU AU2024216443A patent/AU2024216443A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024109615A5 (enExample) | ||
| JP2024129016A5 (enExample) | ||
| Fong et al. | Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer | |
| JP2024119856A5 (enExample) | ||
| FI3468573T3 (fi) | Clostridium difficile -infektion hoito | |
| US8586029B2 (en) | Prevention or treatment of immune-relevant disease by modification of microfloral populations | |
| Zidar et al. | Treatment challenges and delivery systems in immunomodulation and probiotic therapies for periodontitis | |
| CN104306981A (zh) | 抗幽门螺杆菌活性抗菌肽胃黏膜纳米粒给药系统制备方法 | |
| Li et al. | The anti-inflammatory effect and mucosal barrier protection of Clostridium butyricum RH2 in ceftriaxone-induced intestinal dysbacteriosis | |
| WO2015149818A1 (en) | Lactobacillus plantarum inducia strain dsm 21379 as hypocholesterolemic agent and antimicrobial agent against clostridium difficile | |
| JP2016193945A (ja) | 細菌性膣炎の治療または予防の方法 | |
| JPWO2020252144A5 (enExample) | ||
| Vitiello et al. | Therapeutic strategies to combat increasing rates of multidrug resistant pathogens | |
| JP2020520917A5 (enExample) | ||
| RU2019141383A (ru) | Способы лечения цервикальной дистонии | |
| CN114747770A (zh) | 一种嗜酸乳杆菌在制备用于预防或治疗抗生素相关性腹泻的食品或药品中的应用 | |
| Liu et al. | Anti-inflammatory probiotics HF05 and HF06 synergistically alleviate ulcerative colitis and secondary liver injury | |
| Li et al. | Chairside live biotherapeutic hydrogel for comprehensive periodontitis therapy | |
| KR102705354B1 (ko) | 특이적인 치료학적 활성을 가진 항생제를, 동일한 치료학적 적응증과 비-전이성 항생제 내성을 가진 락토바실러스 및/또는 비피도박테리움의 동시 사용과 조합하는 병용 방법 | |
| KR20170045247A (ko) | 유산균 함유 조성물 | |
| CN102872004B (zh) | 柚皮素在制备治疗肺炎药物中的应用 | |
| CA3109900A1 (en) | Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile | |
| CN113413402A (zh) | 梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用 | |
| Zhang et al. | Sustained-Release Enteric Formulations of Lactobacillus plantarum Based on Granulation Technology: Preparation and Therapeutic Evaluation in Acute Colitis | |
| Feret et al. | Manipulation of the gut microbiota: probiotics and fecal microbiota transplantation as a treatment option for recurrent Clostridium difficile infection |